Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced and first commercially approved novel mode-of-action program, was discovered using our proprietary target discovery technology, and is being developed by Gilead and Galapagos in inflammatory indications. Galapagos is progressing multiple programs in inflammation, fibrosis, and kidney diseases.
Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ, all with the ticker symbol GLPG.
We have an international investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.